Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


The hetero ring has at least seven members

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514449000 - Oxygen containing hetero ring

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110178166METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).07-21-2011
20090221689Macrocyclic Modulators of the Ghrelin Receptor - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.09-03-2009
20130030044NEW SERIES OF ARTEMISININ DERIVATIVES AND PROCESS FOR PREPARATION THEREOF - This invention relates to the synthesis of certain novel Baylis-Hillman adducts of artremisinin derived aldehyde 2[10′β-deoxoartemisininyl]-ethanal. The capabilities of introduction of three functional groups into a molecule in one step using Baylis-Hillman reaction encouraged us to synthesize some highly functionalized derivatives of artemisinin. These highly functionalized artemisinin derivatives embodied in this document are found to be active against various cancer cell-lines01-31-2013
20090192216Methods for the formulation and manufacture of artesunic acid for injection - A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium phosphate buffered solution to produce an injectable intravenous or intramuscular formulation. The sodium phosphate dissolves and dilutes the artesunic acid powder without caking or frothing resulting in an improved drug product. The invention also relates to the formulation and a method of treating a patient with either uncomplicated or severe and complicated malaria.07-30-2009
20090192215Cytotoxin Compounds and Methods of Isolation - The present invention concerns groups of compounds derived from tunicates of the 07-30-2009
20110196028PCK ACTIVATION AS A MEANS FOR ENHANCING sAPPa SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS - This invention provides a method for isolating and identifying proteins participating in protein-protein interactions in a complex mixture. The method uses a chemically reactive supporting matrix to isolate proteins that in turn non-covalently bind other proteins. The supporting matrix is isolated, and the non-covalently bound proteins are subsequently released for analysis. Because the proteins are accessible to chemical manipulation at both the binding and release steps, identification of the non-covalently bound proteins yields information on specific classes of interacting proteins, such as calcium-dependent or substrate-dependent protein interactions. This permits selection of a subpopulation of proteins from a complex mixture on the basis of specified interaction criteria. The method has the advantage of screening the entire proteome simultaneously, unlike two-hybrid systems or phage display methods which can only detect proteins binding to a single bait protein at a time. The method is applicable to the study of protein-protein interactions in biopsy and autopsy specimens, to the study of protein-protein interactions in the presence of signaling molecules, pharmacological agents or toxins, and for comparison of diseased and normal tissues or cancerous and untransformed cells.08-11-2011
20090270492BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES - Biologically active compounds related to the bryostatin family of compounds, including methods of utilizing the same.10-29-2009
20100048686Perfume Composition For Temperature Sense Control, Sense Control Article, Sense Control Method, And Perfume Map - It is an object of the present invention to discover that a perfume can change a person's temperature sense and humidity sense, to identify a perfume component that can change temperature sense, and to provide a perfume composition for controlling temperature sense that contains this perfume component, and to a sense control method or sense control article such as an aromatic or a cosmetic that is beneficial for controlling temperature sense, and to a perfume map for selecting a perfume suited to controlling temperature sense. The perfume composition is characterized in that a perfume component that changes the temperature subjectively sensed by a person (temperature sense) is contained, and that the perfume component that changes the temperature sense is a perfume component identified on the basis of a temperature image obtained from test subject assessment.02-25-2010
20120245223USE OF GYMNODIMINE, ANALOGUES AND DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH TAU AND B-AMYLOID - The present invention refers to the use of a compound with the chemical structure09-27-2012
20130041021METHODS OF IMPROVING THE PHARMACOKINETICS OF DOXEPIN - Methods of improving the pharmacokinetics of doxepin in a patient.02-14-2013
20090048333Zearalenone Macrolide Derivatives and Uses of the Same - The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I):02-19-2009
20100041745Aigialomycin D and Derivatives Thereof and Their Use in Treating Cancer or Malaria or a Microbial Infection - The invention describes a process for making compound (2), comprising the step of cyclising diene (3). Compound (2) may be aigialomycin D or a derivative thereof or may be elaborated to make aigialomycin D or derivative thereof. Furthermore compound (2) or derivative thereof can be used in treating cancer or malaria or a microbial infection.02-18-2010
20130072550PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS - The present disclosure relates to methods of administering compounds for treating conditions associated with amyloid processing such as Alzheimer's Disease. Methods are disclosed comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need in an amount effective to decrease soluble Aβ-40 or Aβ-42, or to lower total amyloid precursor protein (“APP”). Methods are also disclosed further comprising the step of identifying a subject with increased soluble Aβ-40 or Aβ-42 levels, or elevated APP levels compared to a control population.03-21-2013
20110021613PLANTS EXTRACTS FOR USE IN BRAIN MODULATION - Compounds obtainable from plants, e.g. of the genus 01-27-2011
20090233996AVERMECTIN/BENZOYL PEROXIDE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea.09-17-2009
20090253781Therapeutic compositions - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.10-08-2009
20090012154Antagonists of the transient receptor potential vanilloid 1 and uses thereof - One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the vanilloid receptor TRPV1 and respond to capsaicin. Resiniferatoxin is a very potent capsaicin analogue that has a much more favorable ratio of desensitization to excitation than capsaicin leading to more effective desensitization without irritation. The present invention demonstrates that desensitization of TRPV1 responsive gastric sensory neurons would attenuate nausea and vomiting.01-08-2009
20090082425COMPOUNDS FROM MYROTHECIUM SP. FOR INHIBITING THE GROWTH OF CANCER CELLS - The present invention relates to a tumor-inhibiting compound, in particular to verrucarin A and verrucarin J isolated from 03-26-2009
20080306138STABLE NON-AQUEOUS POUR-ON COMPOSITIONS - The present invention relates to a stable, antiparasitic, non-aqueous pour-on parasiticidal composition which comprises an effective amount of amitraz, optionally a macrocyclic lactone, a stabilizer and a carrier system having no active hydroxyl group.12-11-2008
20080293805DRUG DELIVERY SYSTEM AND THE PREPARING METHOD THEREOF - A drug delivery system comprises a liposome and at least one charged nanoparticle. The liposome has at least an internal lipid layer and an external lipid layer, wherein the internal lipid layer forms an interior space for accommodating a drug. The charged nanoparticle is reversibly associated with an exterior surface of the external lipid layer of the liposome.11-27-2008
20110034547CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - A composition comprising a substantially purified compound of the formula:02-10-2011
20110166215METHODS OF IMPROVING THE PHARMACOKINETICS OF DOXEPIN - Methods of improving the pharmacokinetics of doxepin in a patient.07-07-2011
20090163575SOLVENT SYSTEMS FOR POUR-ON FORMULATIONS FOR COMBATING PARASITES - This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on formulations comprising a composition comprising a flukicide, such as, for example, clorsulon (4-amino-6-trichloroethenyl-1,3-benzene disulfonamide) and/or a macrolide anthelmintic or antiparasitic agent. In other embodiments, the invention provides pour-on formulations comprising at least one active agent, a glycol ether, and a stability enhancer. This invention also provides for methods for eradicating, controlling, and/or preventing parasite infestation in animals, such as cattle and sheep.06-25-2009
20090209632Percutaneously Absorptive Ophthalmic Preparation Comprising Olopatadine - The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.08-20-2009
20110288163METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.11-24-2011
20120190734COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION - Compounds from 07-26-2012
20100292315 METHOD FOR THE TREATMENT OF FOOD, FEED AND AGRICULTURAL PRODUCTS WITH A POLYENE ANTIFUNGAL COMPOUND - The present invention provides an aqueous antifungal composition comprising a polyene antifungal compound and a thickening agent. The composition can be used in the protection against the development of fungi on food, feed and agricultural products.11-18-2010
20090069412DEUTERIUM-ENRICHED SUGAMMADEX - The present application describes deuterium-enriched sugammadex, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-12-2009
20120122964BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES - Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.05-17-2012
20100113582METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS - Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.05-06-2010
20100249222METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS - A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-α) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting skin or a skin cell with an aromatic skin-active ingredient.09-30-2010
20120065256MILBEMYCIN COMPOUNDS AND TREATMENT OF DERMATOLOGICAL DISORDERS IN HUMANS THEREWITH - Compounds of the milbemycin family or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.03-15-2012
20100087516ANTIBACTERIAL MACROLACTIN A THAT BACILLUS POLYFERMENTICUS KJS-2 PRODUCED IN - The present invention relates to uses of Macrolactin A produced by 04-08-2010
20090286866Double compartment skincare products comprising avermectin/milbemycin compounds - Double compartment skincare products confine a first compartment containing an anhydrous composition including an active ingredient, and a second compartment, wherein the active ingredient is selected from among compounds of the avermectin family and compounds of the milbemycin family, and are useful as medicaments for the treatment and/or prevention of dermatological conditions/afflictions.11-19-2009
20080275107TOPICAL FORMULATIONS AND METHODS FOR ELIMINATION AND PROPHYLAXIS OF SUSCEPTIBLE AND TREATMENT RESISTANT STRAINS OF HEAD LICE WITH MULTIPLE MODES OF ACTION - Topical formulations for prophylaxis or elimination of susceptible and treatment resistant head lice wherein the formulation is an aqueous dispersion of an oil phase containing an effective amount of an active ingredient component combining at least one compound that binds to glutamate-gated chloride ion channels and at least one compound that binds to gamma-amino butyric acid (GABA) receptors, dissolved in at least one water-soluble or water-miscible surface active agent with one or more suspending agents and one or more non-ionic surfactants. Also disclosed are methods of using the topical formulations to treat or prevent an infestation of either a susceptible or treatment resistant strain of head lice in a human patient.11-06-2008
20090042971METHOD OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). 02-12-2009
20080275108VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF - The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of a compound of the present invention. The compound of the present invention has the formula:11-06-2008
20080280973Laulimalide Analogues as Therapeutic Agents - Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.11-13-2008
20090264516Milbemycin compounds and treatment of dermatological disorders in humans therewith - Compounds of the milbemycin family or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.10-22-2009
20100137419ANTI-CANCER AGENT - Disclosed is a novel anti-cancer agent which is less likely to be excreted from a cancer cells and is suitable for the local treatment against a cancer cell. The anti-cancer agent comprises a rotaxane compound represented by chemical formula (I) as an active ingredient. The rotaxane compound is composed of two moieties; namely, a rod-like moiety having a relatively large molecule attached to each of both ends, and a cyclic moiety (a crown ether) into which the rod-like moiety has been inserted. The cyclic moiety cannot be detached from the rod-like moiety, because the rod-like moiety has a relatively large molecule attached to each of both ends and the relatively large molecules serves as a stopper for the detachment. The bond between the two moieties is not a covalent bond. Therefore, the shape of the molecule can be varied readily, and the uptake of the molecule via a receptor becomes relatively difficult. However, once the molecule is introduced into a cancer cell, the proliferation of the cancer cell can be inhibited.06-03-2010
20090069413DEUTERIUM-ENRICHED OLOPATADINE - The present application describes deuterium-enriched olopatadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-12-2009
20090082426DIMERS OF ARTEMISININ DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The present invention relates to dimers of artemisinin derivatives, to processes for the preparation of such dimers, to methods of treatment comprising administration of such dimers, and to intermediates to such dimers.03-26-2009
20090197938Polyphenol Type Compounds, Compositions Containing Same and Use Thereof for Preventing or Treating Diseases Involving Abnormal Cell Proliferation - The invention concerns compounds of formula (I), wherein —X08-06-2009
20090197939METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS - A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-α) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting skin or a skin cell with an aromatic skin-active ingredient.08-06-2009
20090197940CHONDROPSIN-CLASS ANTITUMOR V-ATPase INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - A composition comprising a substantially purified compound of the formula:08-06-2009
20090209633Treatment of Pain With Resiniferatoxin and Related Analogs - A method of treating inflammatory pain conditions is provided that involves administering an effective amount of a TRPV1 agonist, such as resiniferatoxin, tinyatoxin and related potent agonists and their analogs, to a patient to selectively induce nerve terminal depolarization block and/or nerve terminal death in select TRPV1-containing neurons, to provide the desired pain relief without significant permanent damage to cell bodies of the select TRPV-1 containing neurons.08-20-2009
20090247616USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY - The present invention is a method for the treatment of anxiety and related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment of anxiety and related disorders, which includes mono-therapy and alternatively, co-therapy with at least one anxiolytic.10-01-2009
20090099252NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS - Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.04-16-2009
20100160424RENIN INHIBITORS - Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.06-24-2010
20090048332Natural Novel Antioxidants - New antioxidants derived from lichen extracts are reported; lecanoric acid, erythrin, sekikaic acid, and lobaric acid were reported as potent natural antioxidants for the treatment of disease and protection of products from the effect of oxidizing components.02-19-2009
20100184846Methods for the formulation and manufacture of artesunic acid for injection - A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium phosphate buffered solution to produce an injectable intravenous or intramuscular formulation. The sodium phosphate dissolves and dilutes the artesunic acid powder without caking or frothing resulting in an improved drug product. The invention also relates to the formulation and a method of treating a patient with either uncomplicated or severe and complicated malaria.07-22-2010
20100190843Tubulin Isotype Screening in Cancer Therapy Using Halichondrin B Analogs - Chemotherapeutic agents that interfere with microtubule assembly or disassembly in the cell are potent inhibitors of cell replication. Examples of such agents include halichondrin B analogs. It has been shown that the susceptibility of certain cancers to analogs of halichondrin B correlates with the expression of particular tubulin isotypes or other microtubule-associated proteins such as MAP-4 and stathmin. Correlations such as these may be used in identifying patients suitable for treatment using a particular chemotherapeutic agent. Such a system avoids treating patients with cytotoxic compounds where there is a minimal or no effect on the cancer. The invention also provides a system of establishing these correlations for different compounds and cancer types. The system will be particularly useful in establishing correlations between anti-microtubule agents and cancers such as lung, breast, and ovarian cancer. Kits and reagents useful in practicing the invention are also provided.07-29-2010
20100197777Synergistic combination of analgesic compounds - The present invention relates to a pharmaceutical composition comprising as active substances: 08-05-2010
20100216869ARTEMISININ DERIVATIVES FOR THE TREATMENT OF MELANOMA - The invention relates to Artemisinin derivatives of general formula (I)08-26-2010
20100227917EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE - The present invention provides an eye drop comprising: a dibenz[b,e]oxepine derivative or a salt thereof and a polyvalent weak acid, an acidic amino acid or an amide thereof, a basic amino acid or an amide thereof, or the salt thereof, and the like, for the purpose of providing an eye drop or a preparation for topical administration which enables the concentration of a dibenz[b,e]oxepin derivative or a salt thereof to be high; or an eye drop or a preparation for topical administration comprising the dibenz[b,e]oxepine derivative or the salt thereof and having an effective composition for treating allergic disturbance or inflammatory disorder of an eye or for treating allergic disturbance or inflammatory disorder of a nose.09-09-2010
20100227916N-DESMETHYL-DOXEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.09-09-2010
20130137759COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASE - The present invention features compositions and methods for treatment of parasitic diseases and cancer. The compositions include 05-30-2013
20130143956LONG-ACTING INJECTABLE MOXIDECTIN FORMULATIONS AND NOVEL MOXIDECTIN CRYSTAL FORMS - This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.06-06-2013
20100179215DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders07-15-2010
2011003992218beta-GLYCYRRHETINIC ACID DERIVATIVES AND SYNTHETIC METHOD THEREOF - The present invention provides a chemical compound having the structure being one selected from a group consisting of02-17-2011
20120245222METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).09-27-2012
20100056616IEJIMALID ANALOGA AND USES THEREOF - The invention relates to Iejimalides having the following formula (I) in which a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p are simple or double bonds, the continuous lines representing at least one simple bond, the dotted lines representing a possible bond. A double bond can be present but it is not necessary, and provided that a continuous line is also present, or a simple bond can be present if no other line is represented; m=0-20 and n1-n18=1, 2. The bonds can be used as chemotherapeutic agents for treating cancer.03-04-2010
20090215884METHOD FOR WOUND HEALING - The present invention relates generally to methods and compositions for promoting wound healing in a subject. In particular, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in wound healing and compositions therefor which contain such compounds.08-27-2009
20100063137Cytotoxin Compound And Method of Isolation - The present invention concerns compounds derived from tunicates of the species 03-11-2010
20090030068Antitumour Compounds - The invention relates to novel antitumor compounds of general formula01-29-2009
20100069474NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS - The present invention is directed to novel coumarin derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels03-18-2010
20120065257USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE - The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment and/or prevention of migraine, which includes mono-therapy and alternatively, co-therapy with at least anti-migraine agent.03-15-2012
20080249162PALMEROLIDES: METHODS OF PREPARATION AND DERIVATIVES THEREOF - Organic compounds having Formulas I and II are provided where the variables have the values described herein.10-09-2008
20090203770COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING Bcl-2 FAMILY MEMBER PROTEINS - The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.08-13-2009
20080275106Anticancer and Antiprotozoal Dihydroartemisinene and Dihydroartemisitene Dimers with Desirable Chemical Functionalities - This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor or anti-metastasis agents, one that has shown promising activity against solid tumors.11-06-2008
20080214657TOPICAL AVERMECTIN FORMULATIONS AND METHODS FOR ELIMINATION AND PROPHYLAXIS OF SUSCEPTIBLE AND TREATMENT-RESISTANT STRAINS OF HEAD LICE - An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus 09-04-2008
20080214656Compounds With Diphenoyl-Structure For the Treatment of Immune Diseases - A composition comprising compounds with a diphenoyl (DP 5 structure for preventing or treating an immune disease and a prophylactic or therapeutic method for the immune disease based on the application of the compounds are provided. The compounds with the DP structure increase the number and activity of regulatory T cells involved in regulating an accelerated immune system. Also, the compounds can be an effective prophylactic or therapeutic agent for various immune diseases including transplantation rejection, graft-versus-host diseases, autoimmune diseases, and hypersensitive inflammatory diseases.09-04-2008
20110009479Stimulating Neuronal Growth Using Brevetoxins - Disclosed are methods of treating neurodegenerative diseases or disorders in a subject in need of such treatment. The methods comprise administering to a subject in need of such treatment a therapeutically effective amount of brevetoxin or brevetoxin derivatives. Included in the diseases and disorders are Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, Multiple sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease) and other Motor Neuron Diseases, Prion Diseases, Frontotemporal Dementia (FTD), and CNS dysfunctions such as schizophrenia, depression, and epilepsy. Also included are neurodegenerations resulting from stroke, heart attack, head and spinal cord trauma, traumatic brain injury, bleeding in the brain and other injuries to the central nervous system (CNS).01-13-2011
20110257254Adamantane Derivatives Of Aza-Crown Ethers And Their Use In Treatment Of Tumor - The invention relates to adamantane diaza-crown ether derivatives and the use of mono and diaza-crown ether adamantine derivatives in treatment, especially in tumor treatment. Adamantane aza-crown ethers were obtained by reaction of the corresponding adamantane derived tosylates or adamantane acid chlorides with mono- and diaza-18-crown-6. The prepared compounds showed moderate (monoaza-18-crown-6) to strong (diaza-18-crown-6) antiproliferative and cytotoxic activity on several tumor cell lines, revealing their potential for inhibiting the growth of other tumor cells.10-20-2011
20100179214DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders07-15-2010
20090176868Amidoacetonitrile Derivatives - The invention relates to compounds of the general formula (I) wherein X, Y and W have the significances given in claim 07-09-2009
20090286867COMPOSITIONS AND METHODS OF ADMINISTERING DOXEPIN TO MUCOSAL TISSUE - Compositions and methods for pain relief involve delivery of doxepin to mucosal tissue. Vehicles for administering doxepin may be formulated for sustained release and/or site-specific application to maximize beneficial pain relief locally while minimizing significant adverse side effects.11-19-2009
20110190388URSOLIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF - Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative.08-04-2011
20110015260ANTI-MALARIAL PHARMACEUTICAL COMPOSITION - The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.01-20-2011
20090170925Methods for prognosing the ability of a zearalenone analog compound to treat cancer - The instant invention provides methods of prognosing the ability of a zearalenone analog compound to treat a cancer in a subject, methods of prognosing the ability of a zearalenone analog compound to inhibit the growth of a cancer in a subject, and methods of prognosing the ability of a zearalenone analog compound to promote the activation of apoptosis of a cancer in a subject. Methods of treating a cancer in a subject are also provided. The invention also pertains to methods of determining whether a cancer in a subject is sensitive to treatment with a zearalenone analog compound.07-02-2009
20080319049Compounds For the Treatment of Metabolic Disorders - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R12-25-2008
20100216871USE OF COMPOUNDS HAVING CCR ANTAGONISM - It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.08-26-2010
20110306659OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION - Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.12-15-2011
20110306658Novel compound obtained from gamboge resin, and medical uses of the same - Disclosed herein are seventeen new compounds obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds have activities in inhibiting the growth of tumor/cancer cells.12-15-2011
20090042972METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). 02-12-2009
20100216870Novel Genes Encoding a Nystatin Polyketide Synthase and Their Manipulation and Utility - The invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 35; or (b) a nucleotide sequence which is the complement of SEQ ID No. 35; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 35; or (d) a nucleotide sequence hybridising under conditions of high stringency to SEQ ID No. 35, to the complement of SEQ ID No. 35, or to a hybridisation probe derived from SEQ ID No. 35 or the complement thereof; or (e) a nucleotide sequence having at least 80% sequence identity with SEQ ID No. 35; or (f) a nucleotide sequence having at least 65% sequence identity with SEQ ID No. 35 wherein said sequence preferably encodes or is complementary to a sequence encoding a nystatin PKS enzyme or a part thereof. Also provided are part of such molecules and polypeptides (and parts thereof) encoded by such a nucleic acid molecule, and the use of such molecules and polypeptides in facilitating nystatin biosynthesis and in the synthesis of nystatin derivatives and novel polyketide as macrolide structures.08-26-2010
20100056615USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS - The present invention refers to the use of at least one tricyclic diterpenes for the manufacture of a nutraceutical or pharmaceutical for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders.03-04-2010
20120010278Use of Artemisinin for Treating Tumors Induced by Oncogenic Viruses and for Treating Viral Infections - In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.01-12-2012
20120010277AVERMECTIN COMPOUNDS AND TREATMENT OF DERMATOLOGICAL DISORDERS IN HUMANS THEREWITH - Compounds of the avermectin family or derivatives thereof, notably latidectin, are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.01-12-2012
20110092582New Terpenes And Macrocycles - Novel terpenes and macrocycles are activators of TGR5 and can be used for the prevention and/or treatment of Diabetes Type 2, obesity, neuropathy and/or nephropathy.04-21-2011
20090176866Complexes having adjuvant activity - A complex that comprises a narrow molecular weight distribution polymer that includes units derived from an acrylic acid or a salt thereof, and (i) a substance that has pharmacological activity against a pathogenic organism, or (ii) a substance that has pharmacological activity against a cancer, or (iii) one or more agents selected from antigens and immunogens is useful in treating and/or inducing immunity to the pathogenic organism or the cancer, and for inducing immunity to the antigen or immunogen.07-09-2009
20120022150TREATMENT AND PREVENTION OF BENIGN PIGMENTED MOLES (NAEVI) USING ARTEMISININE AND THE DERIVATIVES THEREOF - A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds.01-26-2012
20120022149PHARMACEUTICAL COMPOSITION WITH ENHANCED SOLUBILITY CHARACTERISTICS - There are disclosed pharmaceutical compositions, particularly ophthalmic compositions, that contain relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents. In a preferred embodiment, the composition is a multi-dose topical aqueous ophthalmic composition that contains relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents.01-26-2012
20120059050GARCINIA DERIVATIVE, ITS PREPARING METHOD AND MEDICINAL USE - The present invention relates to a field of pharmaceutical chemistry, more specifically, the present invention relates to a garcinia derivative Formula (I), its preparing method, and medicinal use. Wherein the definitions of R03-08-2012
20120157519TELLERIUM-CONTAINING COMPOUNDS FOR TREATING VIRAL INFECTIONS - Tellurium-containing compounds identified for use in a method of treating, or prophylaxis against, a viral infection caused by an influenza virus, uses thereof and pharmaceutical kits and pharmaceutical corn positions comprising the same, are disclosed. The tellurium-containing compounds disclosed herein are suitable for co-administration with an antiviral agent.06-21-2012
20120071548Therapeutic compositions - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.03-22-2012
20120071549ANTI-INFLAMMATORY COMPOSITION CONTAINING MACROLACTIN A AND A DERIVATIVE THEREOF AS ACTIVE INGREDIENTS - The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel 03-22-2012
20120157518Sublingual Spray Formulation Comprising Dihydroartemesinin - The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and Lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.06-21-2012
20110082194Synergistic Anticoagulant Composition - A composition is provided that, when utilized in combination with warfarin, greatly improves the anticoagulant effects of warfarin in mammalian subjects. The composition is a compound having a naphthohydroquinone ring system substantially similar to the ring system of the reduced form of vitamin K04-07-2011
20100093842Laulimalide Analogs and Uses Thereof - The present invention provides compounds having formula I:04-15-2010
20120316229ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.12-13-2012
20120316228ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.12-13-2012
20120316227CHRYSOPHAENTIN ANTIMICROBIAL COMPOUNDS THAT INHIBIT FTSZ PROTEIN - Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from 12-13-2012
20100010076Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs and Methods of Use and Manufacture Thereof - The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to 01-14-2010
20090018184Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases - Disclosed are compounds that are derivatives of brevetoxin, or PbTx, pharmaceutical formulations comprising the compounds, and methods of regulating mucus transport in a cell, treating mucociliary dysfunction and diseases related to decreased mucus transport, wherein the compounds are of the Formula (I), and Formula (III):01-15-2009
20100324129ECTOPARASITICIDAL METHODS AND FORMULATIONS - Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof.12-23-2010
20080300298Honokiol Derivates For the Treatment of Proliferative Disorders - The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma are provided.12-04-2008
20130018090LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.01-17-2013
20090270493CYCLIC 1-(ACYLOXY)-ALKYL PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF - The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs.10-29-2009
20080255223Treatment and Prevention of Benign Pigmented Moles (Naevi) Using Artemisinine and the Derivatives Thereof - A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds.10-16-2008
20080249161Dermo-Cosmetic Composition For Pets - The invention relates to a dermo-cosmetic composition for pets. This composition includes a diffusion solvent vehicle that enables, by a simple application to one or more points of the cutaneous surface, a diffusion over the entirety thereof and at the level of the sebaceous glands. The active ingredients, primarily include a complex of essential oils and poly-unsaturated fatty acids, stored in the sebaceous glands, can be salted out progressively with the sebum product to the surface of the skin.10-09-2008
20080227851LAULIMALIDE AND LAULIMALIDE ANALOGS - Novel laulimalide analogs, methods for the treatment of proliferative disease and processes for the synthesis of laulimalide and novel laulimalide analogs are described.09-18-2008
20090176867USE OF N-(DIBENZ(B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT THEREOF FOR THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY - The invention relates to the use of a compound of the formula (I)07-09-2009
20130096188DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders04-18-2013
20130102658DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders04-25-2013
20080207742Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury - The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C(PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.08-28-2008
20130150434METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of treating sleep disorders by administration of low doses of doxepin in individuals seeking sustained efficacy or in need of avoiding weight gain, rebound insomnia, or sedative tolerance resulting from doxepin treatment.06-13-2013
20120283321USE OF GAMBIEROL FOR TREATING AND/OR PREVENTING NEURODEGENERATIVE DISEASES RELATED TO TAU AND BETA-AMYLOID - The present invention relates to the use of a compound with the following chemical structure:11-08-2012
20090203771NOVEL INTERMEDIATE FOR HALICHONDRIN B ANALOG SYNTHESIS AND NOVEL DESULFONYLATION REACTION USED FOR THE INTERMEDIATE - The present invention provides a novel method for producing a compound represented by formula (III) shown below, which comprises treating a compound represented by formula (I) shown below with a trivalent chromium compound and at least one kind of metal selected from the group consisting of manganese and zinc in a solvent in the presence of a ligand represented by formula (II) shown below, and the present invention further provides the novel compound represented by formula (I).08-13-2009
20120295967HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION - The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.11-22-2012
20120071547COMPOUNDS FROM SOFT CORAL, METHOD OF PREPARATION AND PHARMACEUTICAL USES THEREOF - The invention relates to compounds from the soft coral and the generation thereof. The invention also relates to the uses of the compounds from the soft coral in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2.03-22-2012
20120088822LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.04-12-2012

Patent applications in class The hetero ring has at least seven members